FIGURE 1.

CONSORT flow diagram of Japanese patients enrolled in KEYNOTE‐024 to evaluate pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer. ^aThe remaining patients did not meet study eligibility criteria (n = 14). ^bIncludes 10 patients who crossed over to pembrolizumab treatment during the study. ^cIncludes clinical progression. PD‐L1, programmed death ligand 1; TPS, tumor proportion score